Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (8MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-546259
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.54625
Zusammenfassung
Background: The approval of Atezolizumab / Bevacizumab therapy (Atezo/Bev) in 2020 opened up a promising new treatment option for patients with end-stage hepatocellular carcinoma (HCC). However, liver transplant (LTx) patients with HCC are still denied this therapy owing to concerns about ICI-induced organ rejection and lack of regulatory approval. Methods: A prospective observational study at ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags